Related Experiment Video

Updated: Sep 28, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Mantle cell lymphoma: new treatments targeted to the biology

Francesco Bertoni1, Michele Ghielmini, Franco Cavalli

  • 1Department of Experimental Hematology, Bart and The London Queen Mary's School of Medicine and Dentistry, London, United Kingdom.

Clinical Lymphoma
|November 19, 2002
PubMed

Insights

Mantle cell lymphoma (MCL) has a poor prognosis and inadequate response to standard treatments. New targeted therapies, including monoclonal antibodies, show promise for improving outcomes in MCL patients.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin lymphoma with a historically poor patient prognosis.
  • Conventional treatment strategies for MCL often yield inadequate responses and limited long-term survival.
  • Understanding the specific biology and genetic underpinnings of MCL is crucial for developing effective therapies.

Purpose of the Study:

  • To review current and emerging treatment modalities for mantle cell lymphoma.
  • To highlight novel therapeutic strategies targeting MCL-specific molecular pathways.
  • To discuss the role of monoclonal antibodies in the clinical management of MCL.

Main Methods:

  • Comprehensive literature review of preclinical and clinical studies on MCL treatment.
  • Analysis of data on monoclonal antibodies targeting cell surface molecules in MCL.
  • Synthesis of information on novel therapeutic approaches and their biological rationale.

Main Results:

  • Monoclonal antibodies targeting specific molecules on MCL cells are established in clinical practice.
  • Emerging therapies demonstrate potential for improved efficacy in MCL.
  • Research is actively exploring new treatment avenues based on MCL biology and genetics.

Conclusions:

  • Mantle cell lymphoma remains a challenging malignancy requiring innovative therapeutic approaches.
  • Targeted therapies, particularly monoclonal antibodies, represent a significant advancement in MCL treatment.
  • Continued research into MCL biology and genetics is essential for further therapeutic progress.

More Related Videos

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...